153 related articles for article (PubMed ID: 26581586)
1. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.
Santabarbara G; Maione P; Rossi A; Gridelli C
Expert Opin Pharmacother; 2016; 17(4):561-70. PubMed ID: 26581586
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
Duval M; Daniel SJ
J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
[TBL] [Abstract][Full Text] [Related]
4. Optimal control of acute cisplatin-induced emesis.
Verweij J; de Wit R; de Mulder PH
Oncology; 1996 Jun; 53 Suppl 1():56-64. PubMed ID: 8692553
[TBL] [Abstract][Full Text] [Related]
5. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
6. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
8. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents.
Santos NAGD; Ferreira RS; Santos ACD
Food Chem Toxicol; 2020 Feb; 136():111079. PubMed ID: 31891754
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of the side effects of cancer chemotherapy].
Iki S; Urabe A
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1635-40. PubMed ID: 11057312
[TBL] [Abstract][Full Text] [Related]
10. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
Suzuki C; Hiura K; Sato H; Komori H; Yamamoto M
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1653-7. PubMed ID: 21996961
[TBL] [Abstract][Full Text] [Related]
12. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
13. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
14. d-Methionine protects against cisplatin-induced neurotoxicity in cortical networks.
Gopal KV; Wu C; Shrestha B; Campbell KC; Moore EJ; Gross GW
Neurotoxicol Teratol; 2012; 34(5):495-504. PubMed ID: 22732230
[TBL] [Abstract][Full Text] [Related]
15. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis.
Perez EA; Gandara DR
Semin Oncol; 1994 Jun; 21(3 Suppl 5):15-21. PubMed ID: 8042032
[No Abstract] [Full Text] [Related]
16. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
[TBL] [Abstract][Full Text] [Related]
17. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.
Karasawa T; Steyger PS
Toxicol Lett; 2015 Sep; 237(3):219-27. PubMed ID: 26101797
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Maeda A; Ura T; Asano C; Haegawa I; Nomura M; Komori A; Narita Y; Taniguchi H; Kadowaki S; Muro K; Horio Y; Yoshida T; Oze I; Kajita M; Mizutani A
Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
20. Use of high-dose cisplatin with aprepitant in an outpatient setting.
Furukawa N; Kawaguchi R; Kobayashi H
Eur J Cancer Care (Engl); 2012 Jul; 21(4):436-41. PubMed ID: 21883567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
